
LQDA Stock Forecast & Price Target
LQDA Analyst Ratings
Bulls say
Liquidia Corp has demonstrated a positive trajectory in its financial outlook, particularly with the strong launch ramp of YUTREPIA, reflected in the revised peak sales estimates increasing from $1.2 billion to a range of $1.7 billion to $2 billion. The operating profitability achieved in the first full quarter of YUTREPIA's launch indicates strong market acceptance, supported by an improved conversion rate of 85% for patients being switched to YUTREPIA. Furthermore, strategic financial agreements with major payors and the favorable competitive positioning of its novel delivery device enhance potential market penetration and revenue growth opportunities.
Bears say
Liquidia Corp faces considerable legal risks that could threaten the exclusivity of its primary revenue source from YUTREPIA, which is a significant contributor to its top-line growth. Should the company not prevail in ongoing legal challenges related to patent assertions and trade secret misappropriation, it may face substantial financial penalties and disruptions in sales. Furthermore, the uncertainty surrounding YUTREPIA's freedom to operate could explain the current large discount to Liquidia's growth potential, reflecting broader concerns about the sustainability of its revenue stream amidst these legal challenges.
This aggregate rating is based on analysts' research of Liquidia Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.
LQDA Analyst Forecast & Price Prediction
Start investing in LQDA
Order type
Buy in
Order amount
Est. shares
0 shares